miR-155 inhibitors / Novartis - LARVOL DELTA

RG5942 A MIR-155 PHARMACOLOGICAL BLOCKER, MODULATES MICROGLIA RESPONSE AND MITIGATES COGNITIVE IMPAIRMENT IN ALZHEIMER'S DISEASE (ADPD 2024) - "Our study unveils a novel miR-155-mediated regulatory mechanism in MGnD microglia and suggests that targeting miR-155 could be a promising therapeutic strategy for AD. Blocking miR-155 holds the potential to limit neurodegenerative pathology and preserve cognitive function in AD."

Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Cognitive Disorders • Multiple Sclerosis • APOE • CX3CR1 • IFNG • MIR155

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard’s Brigham and Women’s Hospital (PRNewswire) - "Regulus Therapeutics Inc...announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease). Regulus is pursuing this effort in collaboration with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women's Hospital (BWH) and the Foundation for Neurologic Diseases (Boston, MA). The early-stage collaboration began in September 2021, and has now advanced to evaluation of compounds of interest in ALS preclinical in vivo models...Preliminary data for these in vivo preclinical studies are expected in the second half of 2023."

Licensing / partnership • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders